PUBLISHER: DelveInsight | PRODUCT CODE: 1120524
PUBLISHER: DelveInsight | PRODUCT CODE: 1120524
DelveInsight's, "Chronic hand eczema - Pipeline Insight, 2022," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic hand eczema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Hand eczema is a very common and widespread condition, which was presumably first described in the 19th century. It is a frequently encountered problem, affecting individuals of various occupations. Variety of factors may take part in the causation of this condition including endogenous and external/environmental factors acting either singly or in combination. In the 19th century, dermatologists described several morphological variants of hand eczema such as eczema solare, rubrum, impetiginoides, squamosum, papulosum, and marginatum. Chronic hand eczema (CHE) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers. Topical therapeutics comprise the standard of care, but up to 65% of cases do not resolve after treatment, and moderate-to-severe cases are often resistant to topical therapeutics and require systemic options instead.
"Chronic hand eczema - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic hand eczema pipeline landscape is provided which includes the disease overview and Chronic hand eczema treatment guidelines. The assessment part of the report embraces, in depth Chronic hand eczema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic hand eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic hand eczema R&D. The therapies under development are focused on novel approaches to treat/improve Chronic hand eczema.
This segment of the Chronic hand eczema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
ARQ-252 is a topical janus kinase 1 (JAK1) inhibitor that has promise as a novel treatment for inflammatory dermatologic diseases, including chronic hand eczema and vitiligo. Many inflammatory cytokines and other signaling molecules rely on the JAK pathway, and specifically JAK1, which plays a central role in immune system function. Inhibition of JAK1 has been shown to treat a range of inflammatory diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, and atopic dermatitis. ARQ-252 is differentiated from other topical JAK inhibitors by its high potency and unique high selectivity against JAK1 compared to JAK2. ARQ-252's selectivity for JAK1 may confer important safety advantages compared to other topical JAK inhibitors.
ASN002 (Gusacitinib) is a potent dual inhibitor of JAK and SYK kinases, which are involved in both cytokine production and signaling. ASN002 inhibits JAK-mediated cytokine signaling and JAK-SYK mediated T- and B-cell proliferation and function. Gusacitinib completed Phase 2 clinical evaluation in moderate-to-severe chronic hand eczema (CHE) patients.
This segment of the report provides insights about the Chronic hand eczema drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Chronic hand eczema. The companies which have their Chronic hand eczema drug candidates in the most advanced stage, i.e. Phase III include Arcutis Biotherapeutics.
DelveInsight's report covers around 5+ products under different phases of clinical development like:
Chronic hand eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
Products have been categorized under various Molecule types such as:
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic hand eczema therapeutic drugs key players involved in developing key drugs.
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic hand eczema drugs.